Eleven Biotherapeutics appoints Gary Sternberg as Executive Vice President Corporate and Business Development

8 May 2014

US-based Eleven Biotherapeutics (Nasdaq: EBIO), a clinical-stage biopharmaceutical company developing protein therapeutics to treat eye diseases, has announced the appointment of Gary Sternberg as Executive Vice President of Corporate and Business Development.

Dr Sternberg brings more than 20 years of ophthalmology expertise including biotechnology and pharmaceutical industry experience and medical practice. Dr Sternberg’s most recent position was as Therapeutic Head of Ophthalmic Medical Affairs for Genentech, a division of the Roche Group.

Prior to Genentech, he served as Executive Director, Strategic Transactions Group for Bristol-Myers Squibb with responsibility for licensing across multiple therapeutic areas. Prior to Bristol-Myers Squibb, Dr Sternberg served as Chief Business Officer for Fovea Pharmaceuticals, an ophthalmic focused biotechnology company, with primary responsibility for corporate development activities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK